

CORPORATE OFFICE :
1st floor, 137 Hubtown Solaris,
N.S. Phadke Road, Opp. Teli Gali,
Near Andheri East West Flyover Bridge,
Andheri East. Mumbai - 400069 (INDIA).
CIN No. L24232MP1989PLC005390
Tel. : 91-22-6863 4200 / 6863 4206
Fax : (91) 022-2206 3929
E-mail : poltd@panchsheelorganics.in
Website : <http://www.panchsheelorganics.com>



**Panchsheel
Organics
Limited**
MFGRS. OF: BULK DRUGS
& FORMULATIONS

Date: 14th February, 2025

To,
BSE Limited,
P. J. Tower, Dalal Street,
Fort, Mumbai – 400001

Scrip Code: 531726

Dear Sir/Madam,

Sub: Integrated Filing – Financial for the quarter ended December 31, 2024

Ref: SEBI Circular No. – SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024 and read with BSE Circular No. 20250102-4 dated January 02, 2025

Pursuant to SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024 read with read with BSE Circular No. 20250102-4 dated January 02, 2025, please find enclosed herewith the Integrated Filing – Financial for the quarter ended December 31, 2024.

This is for your information and records.

Thanking you,

For Panchsheel Organics Limited

Mahendra Abhaychand Turakhia
Managing Director
DIN:00006222

STATEMENT OF UN-AUDITED (STANDALONE) FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2024

SR. No.	PARTICULARS	Rs. In lacs					
		Quarter Ended			Year to date figure		Year ended
		3 months ended 31.12.2024 (Un-audited)	Preceding 3 months ended 30.09.2024 (Audited)	Corresponding 3 months ended 31.12.2023 (Un-audited)	31/12/2024 (Un-audited)	31/12/2023 (Un-audited)	12 Months ended 31.03.2024 (Audited)
1	Income						
	Revenue from operations	2,624.39	2,718.18	2,561.26	7,947.97	7,394.89	10,521.87
	Other Income	95.50	70.09	121.58	239.78	232.79	245.80
	Total Income	2,719.89	2,788.27	2,682.84	8,187.75	7,627.69	10,767.67
2	Expenses						
	a Cost of materials consumed						
	b Purchases of stock-in-trade	1,303.98	1,759.15	1,241.13	4,527.61	3,878.50	5,179.56
	c Changes in inventories of finished goods, work-in-progress and stock-in-trade	301.98	238.16	420.87	711.98	799.31	1,730.51
	d Employees benefit expense	(16.92)	(351.10)	12.15	(233.14)	30.54	(58.59)
	e Finance costs	189.24	198.58	159.71	551.74	475.20	654.68
	f Depreciation, depletion and amortisation expense	7.65	14.22	4.53	27.81	21.02	26.74
	g. Other Expenses	58.02	56.25	38.96	168.32	117.66	173.85
	1 Power and Fuel						
	2 Other Expenses	26.50	23.24	24.32	67.68	76.63	99.96
	Total other expenses	365.54	336.89	212.29	911.85	713.86	1,022.08
	Total expenses	392.05	360.13	236.61	979.53	790.49	1,122.04
3	Total Profit / Loss before exceptional items and tax	2,236.00	2,275.37	2,113.96	6,733.86	6,113.72	8,828.79
4	Exceptional Items	483.89	512.90	568.88	1,453.89	1,513.96	1,938.88
5	Total Profit / Loss before tax	483.89	512.90	568.88	1,453.89	1,513.96	1,938.88
6	Tax expense						
7	Current tax						
8	Prior year Tax Adjustment	117.00	134.20	143.17	365.64	381.03	525.67
9	Deferred tax	-	-	-	-	-	-
10	Total tax expenses	117.00	134.20	143.17	365.64	381.03	528.12
11	Net movement in regulatory deferral account balances related to profit or loss						
12	Net Profit / Loss for the period from continuing operations	366.89	378.70	425.71	1,088.25	1,132.93	1,410.76
13	Profit / Loss from discontinued operations before tax	-	-	-	-	-	-
14	Tax expense of discontinued operations	-	-	-	-	-	-
15	Net Profit / Loss from discontinued operation after tax	-	-	-	-	-	-
16	Share of Profit / Loss of associates and joint ventures accounted for using	-	-	-	-	-	-
17	Total Profit / Loss for period	366.89	378.70	425.71	1,088.25	1,132.93	1,410.76
18	Items that will not be reclassified to profit or loss	-	-	2.85	-	8.56	(61.39)
19	Income Tax relating to items that will not be reclassified to profit or loss	-	-	(0.72)	-	(2.15)	15.45
20	Total comprehensive Income net of taxes	366.89	378.70	427.84	1,088.25	1,139.34	1,364.82
21	Total Profit / Loss, attributable to						
	Profit / Loss, attributable to owners of parent	-	-	-	-	-	-
	Total Profit / Loss, attributable to non-controlling interests	-	-	-	-	-	-
22	Total Comprehensive income for the period attributable to						
	Comprehensive income for the period attributable to owners of parent	-	-	-	-	-	-
	Total Comprehensive income for the period attributable to owners of parent non-controlling interests	-	-	-	-	-	-
23	Details of equity share capital						
	Paid-up Equity Share Capital	1,317.18	1,317.18	1,178.18	1,317.18	1,178.18	1,317.18
	Face value of equity share capital	10.00	10.00	10.00	10.00	10.00	10.00
24	Details of debt securities						
	Paid-up debt capital	-	-	-	-	-	-
	Face value of debt securities	-	-	-	-	-	-
25	Reserves excluding revaluation reserve						
26	Debt redemption reserve	-	-	-	-	-	11,186.29
27	Earnings per share						
	i. Earnings per equity share for continuing operations						
	Basic earnings (loss) per share from continuing operations	2.79	2.88	3.15	8.26	8.37	11.88
	Diluted earnings (loss) per share from continuing operations	2.79	2.88	2.85	8.26	7.59	10.71
	ii. Earnings per equity share for discontinued operations						
	Basic earnings (loss) per share from discontinued operations	-	-	-	-	-	-
	Diluted earnings (loss) per share from discontinued operations	-	-	-	-	-	-
	iii. Earnings per equity share						
	Basic earnings (loss) per share from continuing and discontinued operations	2.79	2.88	3.15	8.26	8.37	11.88
	Diluted earnings (loss) per share from continuing and discontinued operations	2.79	2.88	2.85	8.26	7.59	10.71
28	Debt equity ratio	-	-	-	-	-	-
29	Debt service coverage ratio	-	-	-	-	-	-
30	Interest service coverage ratio	-	-	-	-	-	-
31	Disclosure of notes on financial results						

NOTE S:

- The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 14th February, 2025. The Results are accompanied by the Limited Review Report.
- Figures for the previous periods have been regrouped, wherever necessary to make them comparable with current period.
- The Company operates in one reportable segments viz. "Manufacturing and Trading of Bulk Drug and Intermediate", in accordance with Ind AS 108 "Operating Segments".
- The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 [Ind AS] prescribed under section 133 of the Companies Act, 2013.
- Directors of the Company propose dividend @8% amounting 0.80 Per Share

Date : 14th February, 2025
 Place : Mumbai

For Panchsheel Organics Limited

Mr. Mahendra A. Kulkarni
 Director
 DIN : 00006122



Limited Review Report

To the Board of Directors of Panchsheel Organics Limited

I have reviewed the accompanying statement of Unaudited Standalone Ind-AS Financial Results of M/s. Panchsheel Organics Limited ("the Company") for the quarter and year to date ended 31st December, 2024, together with the notes thereon attached herewith ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.


I conducted my review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that I plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement.

A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an Audit. I have not performed an audit and accordingly I do not express an audit opinion.

Based on my review conducted as above, nothing has come to my attention that causes me to believe that the accompanying statement of Audited standalone Ind-AS financial results prepared in accordance with applicable Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Jayesh R Shah & Co.
Chartered Accountants
Firm Regn. No.104182W


Jayesh Shah
Proprietor
Membership No.033864



Place: Mumbai
Date: 14th February, 2025
UDIN: 25033864BMNRLN5882

CORPORATE OFFICE :
1st floor, 137 Hubtown Solaris,
N.S. Phadke Road, Opp. Teli Gali,
Near Andheri East West Flyover Bridge,
Andheri East. Mumbai - 400069 (INDIA).
CIN No. L24232MP1989PLC005390
Tel. : 91-22-6863 4200 / 6863 4206
Fax : (91) 022-2206 3929
E-mail : poltd@panchsheelorganics.in
Website : <http://www.panchsheelorganics.com>



**Panchsheel
Organics
Limited**
MFGRS. OF: BULK DRUGS
& FORMULATIONS

- A. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHT ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONAL PLACEMENT ETC.:** - Not Applicable for the Quarter that ended December 31, 2024.
- B. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES** – Not Applicable, No default
- C. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS:**
Not Applicable (applicable only for half-yearly filings i.e., 2nd and 4th quarter)